A Novel atTAK Against Hepatocellular Carcinoma: Overcoming Resistance to Sorafenib

Cell Mol Gastroenterol Hepatol. 2021;12(3):1151-1152. doi: 10.1016/j.jcmgh.2021.06.005. Epub 2021 Jun 25.

Authors

Silvia Pietrobono¹, Davide Melisi²

Affiliations

¹ Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Verona, Italy.
² Digestive Molecular Clinical Oncology Research Unit, Università degli Studi di Verona, Experimental Cancer Medicine Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: [email protected].

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Drug Resistance, Neoplasm
Humans
Liver Neoplasms* / drug therapy
Phenylurea Compounds / therapeutic use
Sorafenib / pharmacology
Sorafenib / therapeutic use

Substances

Phenylurea Compounds
Sorafenib